Vaccine Production is a Collaborative Effort in China

Simcere Pharmaceutical, a leading manufacturer and supplier of branded generic pharmaceuticals, is taking strides to develop cost-effective vaccines in China as this is the fourth largest vaccine market in the world.

Simcere already has widely sold branded vaccines in China, and recently, signed an agreement with Merck to establish a joint venture to provide quality medicines to Chinese patients. This partnership is designed to focus on the area of cardiovascular disease and to offer a combined portfolio of selected medicines from both companies.

The objective of the collaboration is to market generic and innovative pharmaceutical products for the treatment of diseases.

With local vaccine giants and MNCs continuing to acquire smaller companies in Asia, the market is moving in the direction of integration and consolidation. These collaborations will not only benefit local vaccine players, but also help MNCs set foot in Asia and gain access to support offered by many Asian governments.

In the next five years, China is projected to spend $308.5 billion on science and technology!

http://www.biospectrumasia.com/content/041111CHN17408.asp